WSK V101
Alternative Names: WSK-V101Latest Information Update: 26 Aug 2021
At a glance
- Originator Westvac Biopharma
- Class Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Unspecified
Most Recent Events
- 26 Aug 2021 Westvac Biopharma announces intention to submit NDA for an undisclosed indication in Q2 of 2021
- 25 Aug 2021 Preclinical trials in Unspecified (Prevention) in China (IM) prior to August 2021 (Westvac Biopharma pipeline, August 2021)
- 31 Mar 2021 Phase-II/III clinical trials in Unspecified (Prevention) in China (IM) in Q1 of 2021 (Westvac Biopharma pipeline, August 2021)